Showing results (821-830 of 881) with videos related to

Sort By:
Pageof 89
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Digestive Diseases and Sciences|May 1, 2012
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infectionPaul J Clark, Alexander J Thompson, Qianqian Zhu, et al.
The New England Journal of Medicine|September 21, 2023
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19David R Boulware, Christopher J Lindsell, Thomas G Stewart, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 13, 2017
Efficacy of a 4-Food Elimination Diet for Children With Eosinophilic EsophagitisAmir F Kagalwalla, Joshua B Wechsler, Katie Amsden, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
The American Journal of Gastroenterology|October 31, 2024
Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis RiskPamela M Murnane, Majid Afshar, Gabriel Chamie, et al.
JAMA|February 24, 2015
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trialMark S Sulkowski, Joseph J Eron, David Wyles, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
Science Translational Medicine|February 3, 2017
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivityParker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, et al.
Pageof 89